Valeant hires Zoetis's Paul Herendeen as CFO

Credit Suisse Affirms Positive View on Zoetis (ZTS) Amid CFO Transition; Retains 'Outperform' Rating

Credit Suisse affirms Zoetis (NYSE: ZTS) at Outperform with a price target of $60 following news Monday of a new CFO appointment.

The firm commented, Our thesis remains ZTS's highly diverse portfolio, innovation, and increasing focus on faster-growing segments should continue to drive... More

Guggenheim Remains Positive on Zoetis (ZTS) as CFO Departs for Valeant (VRX)

Guggenheim is out with commentary on recent CFO changes at Zoetis (NYSE: ZTS) and Valeant. The firm rates Zoetis at Buy with a price target of $60.

Analyst Louise Chen comemnted, In Specialty Pharma it seems as if conservation of mass applies to senior leadership changes within the industry. Yesterday evening, Zoetis announced... More

Valeant's (VRX) CFO Hire Seen as Positive at Deutsche Bank

Deutsche Bank analyst Gregg Gilbert commented on Valeant Pharma (NYSE: VRX) after the company announced that Paul S. Herendeen will take over the role of CFO. In the analyst's view, the hire is a key positive for Valeant.

"... we see the hiring... More

RBC Capital Positive on Valeant's (VRX) CFO Hire

RBC Capital analyst Douglas Miehm views Valeant Pharmaceuticals' (NYSE: VRX) hiring of Paul Herendeen as EVP and CFO as a positive.

Miehm notes from Herendeen comes from Zoetisc and has over 16 years of public company CFO experience.

"We view the addition... More